← Leaderboards
Edward J McGuire
Cognitive Pharmaceuticals, Ltd
$1,696,059
Attributed
$1,696,059
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $660.5K · FY2005–07$1M$750K$500K$250K$0
'05
'06
'07
Funding mix
By agency
NIH$1,696,059 · 3
By mechanism
R44$1,196,328 · 2
R43$499,731 · 1
Top collaborators
No co-investigators on record.
Most similar at Cognitive Pharmaceuticals, Ltd
Same institution · by research overlap
- Debasis Ghosh$100,000
Others in their field
Top investigators on “Drug Screening /Evaluation”
- Fred M Gordin · Social And Scientific Systems, Inc.$68,001,399
- John C S Breitner · Johns Hopkins University$33,065,187
- Philip J Disaia · University Of California Irvine$21,551,991
- George R Painter · Chimerix, Inc.$19,230,662
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Stephen J Durako · Westat, Inc.$15,048,684
Research focus
Drug Screening /EvaluationDrug Design /Synthesis /ProductionDrug InteractionsCell LineReceptor BindingAnticholinergic AgentStimulant /AgonistLiquid ChromatographyMass SpectrometryHigh Performance Liquid ChromatographySchizophreniaAntipsychotic AgentsApomorphineAnalogMuscarinic ReceptorBlood Brain BarrierDrug Discovery /IsolationCognitionDrug MetabolismEnzyme Linked Immunosorbent AssayLaboratory RatAttentionCanis FamiliarisAmyloid Proteins
Grant awards (5)
Development of a Selective Muscarinic Agonist for the Treatment of Schizophrenia$446,844
R44 · FY2007 · MH · contact PI
Utility of Muscarinic Agonists for Alzheimer's disease$410,796
R44 · FY2005 · AG
Utility of Muscarinic Agonists in Schizopherenia$249,731
R43 · FY2005 · MH
Utility of Muscarinic Agonists for Alzheimer's disease$338,688
R44 · FY2004 · AG
Utility of Muscarinic Agonists in Schizopherenia$250,000
R43 · FY2004 · MH